Schizophrenia is a debilitating and chronic brain disorder which affects 1% of the world population. There is significant evidence to indicate high rates of smoking in this patient population causing additional health problems for this group of individuals. There is a scarcity of studies examining the effects of psychopharmacologic interventions in helping schizophrenic patients to either reduce or stop their tobacco intake. Recent evidence shows superiority of bupropion HCl to placebo in cigarette smoking cessation. Although cessation of smoking should be the ultimate goal, many schizophrenics are unwilling or unable to quit. We would like to test the hypothesis that bupropion will cause reductions in nicotine use by schizophrenic patients. We propose to do a double blind randomized placebo-controlled within subject cross-over study in 10 subjects to establish the feasibility and acceptability of bupropion in this population. We hope that this study will provide pilot data to undertake a subsequent larger, clinical trial.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA013333-02
Application #
6358483
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2000-09-30
Project End
2001-08-31
Budget Start
Budget End
Support Year
2
Fiscal Year
2000
Total Cost
$236,728
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
168559177
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Burns, Rachel J; Rothman, Alexander J; Fu, Steven S et al. (2016) Longitudinal Care Improves Cessation in Smokers Who Do Not Initially Respond to Treatment by Increasing Cessation Self-Efficacy, Satisfaction, and Readiness to Quit: A Mediated Moderation Analysis. Ann Behav Med 50:58-69
Konorev, Dmitri; Koopmeiners, Joseph S; Tang, Yijin et al. (2015) Measurement of the Heterocyclic Amines 2-Amino-9H-pyrido[2,3-b]indole and 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in Urine: Effects of Cigarette Smoking. Chem Res Toxicol 28:2390-9
Hatsukami, Dorothy K; Donny, Eric C; Koopmeiners, Joseph S et al. (2015) Compensatory smoking from gradual and immediate reduction in cigarette nicotine content. Cancer Epidemiol Biomarkers Prev 24:472-6
Burns, Rachel J; Rothman, Alexander J; Fu, Steven S et al. (2014) The relation between social support and smoking cessation: revisiting an established measure to improve prediction. Ann Behav Med 47:369-75
Oliver, Andrew J; Jensen, Joni A; Vogel, Rachel I et al. (2013) Flavored and nonflavored smokeless tobacco products: rate, pattern of use, and effects. Nicotine Tob Res 15:88-92
Knezevich, Aleksandar; Muzic, John; Hatsukami, Dorothy K et al. (2013) Nornicotine nitrosation in saliva and its relation to endogenous synthesis of N'-nitrosonornicotine in humans. Nicotine Tob Res 15:591-5
Anderson, Kristin E; Mongin, Steven J; Sinha, Rashmi et al. (2012) Pancreatic cancer risk: associations with meat-derived carcinogen intake in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) cohort. Mol Carcinog 51:128-37
Stepanov, Irina; Knezevich, Aleksandar; Zhang, Liqin et al. (2012) Carcinogenic tobacco-specific N-nitrosamines in US cigarettes: three decades of remarkable neglect by the tobacco industry. Tob Control 21:44-8
Kotlyar, Michael; Hertsgaard, Louise A; Lindgren, Bruce R et al. (2011) Effect of oral snus and medicinal nicotine in smokers on toxicant exposure and withdrawal symptoms: a feasibility study. Cancer Epidemiol Biomarkers Prev 20:91-100
Joseph, Anne M; Fu, Steven S; Lindgren, Bruce et al. (2011) Chronic disease management for tobacco dependence: a randomized, controlled trial. Arch Intern Med 171:1894-900

Showing the most recent 10 out of 132 publications